Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 1/2012

01-02-2012 | SHORT REPORTS

Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy

Authors: Amélie Lansiaux, Sophie Salingue, Amélie Dewitte, Stéphanie Clisant, Nicolas Penel

Published in: Investigational New Drugs | Issue 1/2012

Login to get access

Summary

Several previous reports suggest that thrombospondin (TSP-1) may be a mediator of the antiangiogenic effects of low-dose metronomic cyclophosphamide-based chemotherapy (MC). We conducted a randomized phase II trial evaluating megestrol acetate (n = 44) versus MC (n = 44) in patients having exhausted all standard treatments. We measured the TSP-1 levels at baseline and D15. We did not observe significant differences in TSP-1 at baseline in the two arms (p = 0.07). TSP-1 levels decreased in patients receiving metronomic cyclophosphamide (from 16.6 ± 7.2 µg/ml to 12.8 ± 7.4 µg/ml; p = 0.057). The TSP-1 level was stable in patients receiving megestrol acetate. Nevertheless, the TSP-1 level driven by MC did not correlate to clinical benefit.
Literature
1.
Kerbel RS, Klement G, Prichard KI, Kamen B (2002) Continuous low dose antiangiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 13:12–15PubMedCrossRef
2.
Buckstein R, Kerbel RS, Shaked Y, Noyar R, Foden C, Turner R et al (2006) High-dose celecoxib and metronomic “low dose” cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin’s lymphoma. Clin Cancer Res 12:5190–5198PubMedCrossRef
3.
Bocci G, Francia G, Man S, Lanler S, Kerbel RS (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100:1297–1222CrossRef
4.
Damber JE, Vallbo C, Albertsson P, Lennernäs B, Norrby K (2006) The antitumor effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 58:354–360PubMedCrossRef
5.
Penel N, Clisant S, Dansin E, Desauw C, Dégardin M, Mortier L et al (2010) Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care. Br J Cancer 102:1207–1212PubMedCrossRef
Metadata
Title
Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy
Authors
Amélie Lansiaux
Sophie Salingue
Amélie Dewitte
Stéphanie Clisant
Nicolas Penel
Publication date
01-02-2012
Publisher
Springer US
Published in
Investigational New Drugs / Issue 1/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-010-9443-1

Other articles of this Issue 1/2012

Investigational New Drugs 1/2012 Go to the issue

SHORT REPORT

Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer

PHASE II STUDIES

A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer

PRECLINICAL STUDIES

3β-acetyl tormentic acid induces apoptosis of resistant leukemia cells independently of P-gp/ABCB1 activity or expression

PRECLINICAL STUDIES

The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma

PRECLINICAL STUDIES

Synthesis and biological evaluation of 2-amino-1-thiazolyl imidazoles as orally active anticancer agents

SHORT REPORT

Anti-leukemic activity of Dasatinib in both p53wild-type and p53mutated B malignant cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits